Saliva samples contain biomarkers—biological markers than can indicate whether or not you have a disease or are likely to develop one. Biological markers also can be used to predict whether a tumor will respond to certain cancer treatments. A research team at Yale University, led by Dr. Joanne Weidhaas, has identified biomarkers that can be used to assess breast cancer risk. In their study, “Hormones, the KRAS-variant, and Breast Cancer Risk”, the team will study the DNA (genetic material) that can be found in a saliva sample to try to learn how known risk factors, such as hormone replacement therapy and other types of estrogen exposure, affect breast cancer risk for women who have these biomarkers.
Thanks to all of you, we not only closed this study to recruitment in 30 days, but the research team will be able to enroll even more women than planned. The research team is enrolling breast cancer survivors nationwide to participate. They originally planned to enroll between 1,000-1,500 breast cancer survivors. After the Army of Women members began responding in high numbers to the e-blast, the team decided to keep the study open and enroll as many women as possible in a one-month period. Doing so will allow them to study a wide variety of survivors, including pre- and post-menopausal women and women with different stages and grades of breast cancer. When the study closed, more than 2,460 women had signed up to be contacted by the research team. Dr. Weidhaas and her team were overwhelmed with the positive response and are enjoying working with the AOW members.